Zymeworks insider sells 19,848 shares in two trades

Zymeworks Inc. insider transactions were reported: director/officer Jeffrey T. L. Smith disclosed open-market dispositions and planned sales of common stock.

Accepted by SEC EDGAR 03/06/2026 - 09:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Zymeworks Inc. insider transactions were reported: director/officer Jeffrey T. L. Smith disclosed open-market dispositions and planned sales of common stock. The filing shows two sales: 10,538 shares on 01/05/2026 for $264,471.13 and 9,310 shares on 01/12/2026 for $211,090.28. The filing also lists securities to be sold on 03/06/2026 tied to an exercise of options (220,625 shares) and multiple upcoming restricted stock unit vestings (9,462; 8,356; 8,890 shares) on 01/05/2026 and 01/12/2026 described as compensation-related transactions.

Insights

Insider Transactions Analyst

Routine insider sale disclosures with examples of past and planned dispositions.

The disclosure lists two completed dispositions by Jeffrey T. L. Smith: 10,538 shares sold on 01/05/2026 for $264,471.13 and 9,310 shares sold on 01/12/2026 for $211,090.28. These are specific, reported transactions filed under Form 144.

Planned transactions are also listed, including an exercise of options for 220,625 shares on 03/06/2026 and several RSU vestings (9,462; 8,356; 8,890 shares) described as compensation. Cash‑flow treatment for the planned sales is not detailed in the excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider sales did ZYME report in this Form 144?

Two specific sales were reported by Jeffrey T. L. Smith. The filing lists sales of 10,538 shares on 01/05/2026 for $264,471.13 and 9,310 shares on 01/12/2026 for $211,090.28.

Does the filing show any planned insider sales for ZYME?

Yes: planned dispositions are listed. The excerpt shows an exercise of options for 220,625 shares on 03/06/2026 and several RSU vestings on 01/05/2026 and 01/12/2026.

Who is the reporting person in the ZYME Form 144?

Jeffrey T. L. Smith is identified as the reporting person. His address is shown c/o Zymeworks Inc., and he reported the two sales with amounts and dates.

What amounts were realized from the reported ZYME insider sales?

Reported proceeds are shown for each sale. The filing records proceeds of $264,471.13 for 10,538 shares and $211,090.28 for 9,310 shares.

Are the RSU vestings in the filing described as compensation?

Yes, several vesting events are labeled compensation. The excerpt lists RSU vestings of 9,462; 8,356; and 8,890 shares tied to compensation on the dates shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001604800
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Zymeworks Inc.
SEC File Number	001-41535
Address of Issuer	108 Patriot Drive, Suite A Middletown DELAWARE 19709
Phone	302-274-8744
Name of Person for Whose Account the Securities are To Be Sold	Jeffrey T L Smith
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Wealth Management Canada 140 4th Ave. SW, Suite 2740 Calgary A0 T2P 3N3	247333	6133858.40	73749607	03/06/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/06/2026	Exercise of Options	Issuer			220625	03/06/2026	Exercise and sell to cover
Common Stock	01/12/2026	Vesting of Restricted Stock Units	Issuer			8356	01/12/2026	Compensation
Common Stock	01/05/2026	Vesting of Restricted Stock Units	Issuer			9462	01/05/2026	Compensation
Common Stock	01/05/2025	Vesting of Restricted Stock Units	Issuer			8890	01/05/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jeffrey T L Smith c/o Zymeworks Inc. 108 Patriot Drive, Suite A Middletown, DE 19709	Common Stock	01/05/2026	10538	264471.13
Jeffrey T L Smith c/o Zymeworks Inc. 108 Patriot Drive, Suite A Middletown, DE 19709	Common Stock	01/12/2026	9310	211090.28

144: Remarks and Signature

Remarks
Date of Notice	03/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeffrey T L Smith
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)